A new device may easily detect Alzheimer's disease

A Child Wearable to Keep Kids Close

Students build smaller, equally powerful version of Village Drill

Comply: Intelligent Pharmaceutical Process Management

Comply specializes in bridging Information Technology (IT) with regulatory requirements in the Life Science domain. Their wide expertise covers areas such as Quality Systems, Data Integrity, Validation of Computerized Systems, Quality of Digital Health systems, Cloud systems and more. Combining the professional services with best practice implementations enable operational excellence and help become a true knowledge-based organization. Comply delivers the highest quality standards by deploying an innovating, proactive approach to regulatory compliance across the full lifecycle of development, manufacturing and quality management processes.

99 days ago

Brain Corp: Transforming everyday machines into autonomous solutions

Brain Corp is a software technology company specializing in the development of autonomous A.I. systems for self-driving vehicles (SDVs). The company was co-founded in 2009 by a world-renowned computational neuroscientist, Dr. Eugene Izhikevich, and serial tech entrepreneur, Dr. Allen Gruber. Brain Corp’s initial work involved advanced R&D for Qualcomm Inc. and DARPA. The company is now focused on developing advanced ML and computer vision systems for the next generation of self-driving robots. Brain Corp is funded by the Softbank Vision Fund and Qualcomm Ventures, the investment arm of mobile technology leader, Qualcomm Inc.


Beam Therapeutics uses CRISPR base editing to develop genetic medicines

Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam Therapeutics is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Headquartered in Cambridge, Massachusetts, the company is backed by F-Prime Capital Partners and ARCH Venture Partners, two of the world’s leading biotech venture capital firms. In addition, Beam Therapeutics has already raised a total of $87 million in Series A round.


Genprex: developing the immunogene therapy for cancer

A mobile application to support education of dyslexic children

CloudCuddle provides mobile and safe sleeping environment for disabled children

Inflazome provides targeted therapies for inflammatory diseases

Inflazome is a biotech company that develops new drugs to block harmful inflammation. The company is creating potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives Alzheimer’s (lat. morbus Alzheimerianus) and Parkinson’s diseases (lat. Parkinson scriptor morbus) as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases. Inflazome has already secured further investment of $63 million. Launched in 2016, Inflazome was founded on research from The University of Queensland and Trinity College Dublin in Ireland. The Series B financing will be used to advance the company's small-molecule inhibitors of the NLRP3 inflammasome in to multiple clinical trials in 2019.


Corsair FEAM: Better Protection from Impact Injury

The breakthrough 100% textile, FEAM (Fiber Energy Absorbing Material) technology has been invented by the researchers at University of Massachusetts Dartmouth (UMASSD). It can be used in sport and military helmets, sports protection padding and fabric armor vests for the military. The FEAM 100% textile construction differs radically from standard foams. FEAM is light, flexible, breathable and can be customized for fit, comfort and impact performance. FEAM is an energy absorbing material that will complement or replace currently used foams. This revolutionary material is made using a mature manufacturing process called flocking but in a new and innovative way. 


Umoove allows mobile a face and eye tracking

Umoove, a Jerusalem-based spinoff, created a face and eye-tracking solution that is compatible with any smartphone or tablet with a front-facing camera. The company's core technology does not require any additional hardware of any kind. Furthermore, the developed in-house medical application is also powering eye tracking research in top universities across the world. Eye tracking and digital biomarkers are used as a method for diagnosis and therapy of many neurological disorders such as Attention deficit hyperactivity disorder (ADHD), concussions, traumatic brain injury, Alzheimer's disease (lat. morbus Alzheimerianus), autism (lat. Autismus), strokes (lat. Apoplexia), amyotrophic lateral sclerosis (amyotrophic lateralibus lumbos) and more. The company's first product, uHealth, was released in 2015. 


Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.